MCID: INT079
MIFTS: 54

Intrahepatic Cholangiocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Intrahepatic Cholangiocarcinoma

MalaCards integrated aliases for Intrahepatic Cholangiocarcinoma:

Name: Intrahepatic Cholangiocarcinoma 12 53 6 15 73
Cholangiocarcinoma 44 73
Peripheral Intrahepatic Cholangiocarcinoma 73
Intrahepatic Bile Duct Carcinoma 12
Peripheral Cholangiocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4928
ICD10 33 C22.1
MeSH 44 D018281
NCIt 50 C35417

Summaries for Intrahepatic Cholangiocarcinoma

NIH Rare Diseases : 53 Intrahepatic cholangiocarcinoma is a cancer that develops in the cells within the bile ducts; both inside and outside the liver. The terms cholangiocarinoma and bile duct cancer are often used to refer to the same condition. This condition occurs slightly more often in males than females and usually affects people who are between 50-70 years old. Signs and symptoms of intrahepatic cholangiocarcinoma include jaundice, abdominal pain, fever, weight loss, weakness and itching. Treatment options may include surgery to remove the bile duct and parts of the liver, chemotherapy and radiation.

MalaCards based summary : Intrahepatic Cholangiocarcinoma, also known as cholangiocarcinoma, is related to cholangiocarcinoma and biliary tract neoplasm, and has symptoms including abdominal pain and malaise. An important gene associated with Intrahepatic Cholangiocarcinoma is CCAT2 (Colon Cancer Associated Transcript 2), and among its related pathways/superpathways are Gastric cancer and CLEC7A (Dectin-1) signaling. The drugs Capecitabine and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include liver, lymph node and neutrophil, and related phenotype is neoplasm.

Related Diseases for Intrahepatic Cholangiocarcinoma

Diseases related to Intrahepatic Cholangiocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 400)
# Related Disease Score Top Affiliating Genes
1 cholangiocarcinoma 32.5 AFP CCAT2 CDH1 IDH1 IDH2 KRAS
2 biliary tract neoplasm 32.3 KRAS KRT7 MUC1 MUC2 MUC4 TP53
3 bile duct cystadenocarcinoma 31.2 AFP KRT7 MUC1 MUC2
4 adenocarcinoma 30.8 CDH1 FGFR2 KRAS MUC1 MUC4 TP53
5 lymphoepithelioma-like carcinoma 30.5 CDH1 KRT7 MUC1
6 bile duct adenoma 30.4 KRT7 MUC1
7 cystadenocarcinoma 30.2 KRT7 MUC1 MUC2 TP53
8 laryngeal squamous cell carcinoma 30.2 CCAT1 CDH1 TP53
9 biliary papillomatosis 30.2 KRAS KRT7 MUC1 MUC2 TP53
10 renal cell carcinoma, nonpapillary 30.1 CCAT1 CDH1 KRT7 MUC1 TUG1
11 squamous cell carcinoma 30.1 CCAT2 CDH1 FGFR2 MUC1 TP53 TUG1
12 pancreas adenocarcinoma 30.0 CDH1 KRAS MUC1 MUC2 MUC4 TP53
13 cholecystitis 30.0 CDH1 MUC1 MUC2 TP53
14 gallbladder cancer 30.0 CCAT1 CDH1 KRAS MUC1 MUC2 TP53
15 adenomyoma 29.9 KRT7 MUC1 MUC4
16 hepatoblastoma 29.9 AFP KRT7 TP53 TUG1
17 clear cell renal cell carcinoma 29.9 CCAT2 CDH1 KRT7 MUC1 TP53 TUG1
18 linitis plastica 29.8 CDH1 KRT7
19 cystadenoma 29.8 KRT7 MUC1 MUC2 MUC4
20 papillary carcinoma 29.8 CDH1 KRT7 MUC1
21 colorectal adenocarcinoma 29.7 CDH1 KRAS KRT7 MUC2 TP53
22 lung squamous cell carcinoma 29.6 CCAT1 CCAT2 CDH1 FGFR2 KRAS TP53
23 gastric adenocarcinoma 29.5 AFP CDH1 FGFR2 KRAS KRT7 MUC1
24 osteogenic sarcoma 29.5 CCAT1 CCAT2 TP53 TUG1
25 hepatocellular carcinoma 29.5 AFP CCAT1 CCAT2 CDH1 CPS1-IT1 IDH1
26 gastric cancer 29.2 AFP CCAT1 CCAT2 CDH1 FGFR2 KRAS
27 colorectal cancer 29.0 CCAT1 CCAT2 CDH1 KRAS KRT7 MIR127
28 pancreatic cancer 28.7 CCAT1 CDH1 KRAS MIR127 MIR214 MIR376A1
29 breast cancer 28.6 CCAT1 CCAT2 CDH1 FGFR2 IDH1 KRAS
30 ovarian cancer 27.8 CCAT1 CCAT2 CDH1 KRAS KRT7 MIR127
31 sarcomatous intrahepatic cholangiocarcinoma 12.5
32 mucinous intrahepatic cholangiocarcinoma 12.5
33 signet ring cell intrahepatic cholangiocarcinoma 12.3
34 klatskin's tumor 11.6
35 hepatitis 10.7
36 hepatitis b 10.6
37 viral infectious disease 10.4
38 hepatitis c 10.4
39 nodular hidradenoma 10.4 KRT7 MUC1
40 aggressive digital papillary adenocarcinoma 10.4 KRAS MUC1
41 bladder carcinoma in situ 10.4 KRT7 TP53
42 mutyh-associated polyposis 10.4 KRAS TP53
43 mixed glioma 10.4 IDH1 TP53
44 biphasic synovial sarcoma 10.4 CDH1 MUC1
45 gastric cancer, hereditary diffuse 10.4 CDH1 KRAS
46 hepatitis c virus 10.4
47 viral hepatitis 10.4
48 interval angle-closure glaucoma 10.3 IDH1 IDH2
49 cap polyposis 10.3 MUC2 MUC4
50 apocrine adenoma 10.3 KRAS MUC1

Graphical network of the top 20 diseases related to Intrahepatic Cholangiocarcinoma:



Diseases related to Intrahepatic Cholangiocarcinoma

Symptoms & Phenotypes for Intrahepatic Cholangiocarcinoma

UMLS symptoms related to Intrahepatic Cholangiocarcinoma:


abdominal pain, malaise

MGI Mouse Phenotypes related to Intrahepatic Cholangiocarcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AFP CDH1 FGFR2 IDH2 KRAS MUC2

Drugs & Therapeutics for Intrahepatic Cholangiocarcinoma

Drugs for Intrahepatic Cholangiocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 117)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Capecitabine Approved, Investigational Phase 3,Phase 1 154361-50-9 60953
2
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
3
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
5
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
6
Bortezomib Approved, Investigational Phase 3 179324-69-7 387447 93860
7
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
8 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
9 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
10 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
11 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
12 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
13 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
14 Alkylating Agents Phase 2, Phase 3
15 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
16 Antineoplastic Agents, Alkylating Phase 2, Phase 3
17 Mitogens Phase 3,Phase 1,Phase 2
18 Endothelial Growth Factors Phase 3
19 Pharmaceutical Solutions Phase 3
20
Fluorouracil Approved Phase 2 51-21-8 3385
21
leucovorin Approved Phase 2 58-05-9 6006 143
22
Metformin Approved Phase 1, Phase 2 657-24-9 14219 4091
23
chloroquine Approved, Investigational, Vet_approved Phase 1, Phase 2 54-05-7 2719
24
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
25
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
26
Floxuridine Approved Phase 2,Phase 1 50-91-9 5790
27
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
28
Fludarabine Approved Phase 1, Phase 2,Phase 2 75607-67-9, 21679-14-1 30751
29
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 6055-19-2, 50-18-0 2907
30
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
31
Irinotecan Approved, Investigational Phase 2 100286-90-6, 97682-44-5 60838
32
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
33
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
34
Nivolumab Approved Phase 1, Phase 2,Phase 2 946414-94-4
35
Ramucirumab Approved, Investigational Phase 2 947687-13-0
36
Pertuzumab Approved Phase 2 145040-37-5, 380610-27-5 2540
37
Osimertinib Approved Phase 2 1421373-65-0
38
Adenosine Approved, Investigational Phase 2 58-61-7 60961
39
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
40
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
41
Trametinib Approved Phase 2 871700-17-3 11707110
42
Crizotinib Approved Phase 2 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
43
Racepinephrine Approved Phase 2 329-65-7 838
44
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
45
Palbociclib Approved, Investigational Phase 2 571190-30-2 11431660 5330286 5005498
46
Dabrafenib Approved, Investigational Phase 2 1195765-45-7 44462760 44516822
47
Atezolizumab Approved, Investigational Phase 2,Phase 1 1380723-44-3
48
Vitamin D Approved, Nutraceutical, Vet_approved Phase 2 1406-16-2
49
Calcitriol Approved, Nutraceutical Phase 2 32222-06-3 5280453 134070
50
Doxil Approved June 1999 Phase 2 31703

Interventional clinical trials:

(show top 50) (show all 72)
# Name Status NCT ID Phase Drugs
1 Oxaliplatin+Gemcitabine vs Capecitabine as Adjuvant Therapy for Intrahepatic Cholangiocarcinoma Unknown status NCT02548195 Phase 3 oxaliplatin and gemcitabine;capecitabine
2 SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT02807181 Phase 2, Phase 3 Cisplatin-gemcitabine
3 Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma Recruiting NCT03086993 Phase 2, Phase 3 Cisplatin and Gemcitabine
4 A Study of Second-line Treatment With Apatinib in Patients With Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03251443 Phase 3 Apatinib
5 HAIC Versus Systemic Chemotherapy for Unresectable ICC Recruiting NCT03771846 Phase 3 gemcitabine, oxaliplatin , fluorouracil, and leucovorin;gemcitabine and oxaliplatin
6 Bortezomib in Intrahepatic Cholangiocellular Carcinoma Recruiting NCT03345303 Phase 3 Bortezomib
7 Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers Recruiting NCT03768414 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel
8 Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery Terminated NCT02200042 Phase 3 Cisplatin;Gemcitabine Hydrochloride
9 A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma Withdrawn NCT03081039 Phase 3 Carboplatin;Cisplatin;Gemcitabine
10 Calcitriol in Advanced Intrahepatic Cholangiocarcinoma Unknown status NCT01039181 Phase 2 Calcitriol
11 Metformin And Chloroquine in IDH1/2-mutated Solid Tumors Unknown status NCT02496741 Phase 1, Phase 2 Metformin and chloroquine combination
12 Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed NCT02428855 Phase 2 Dasatinib
13 Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma Completed NCT01912053 Phase 2
14 Vandetanib Gemcitabine Or Placebo Plus Gemcitabine Or Vandetanib Monotherapy In Advanced Biliary Tract Cancer Completed NCT00753675 Phase 2 ZD6474, Vandetanib;ZD6474, Vandetanib;Gemcitabine;Placebo matching ZD6474
15 Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma Completed NCT01954745 Phase 2 Cabozantinib
16 Study of Orally Administered AG-221 in Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Subjects With Advanced Solid Tumors, Including Glioma, and With Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Completed NCT02273739 Phase 1, Phase 2 AG-221
17 A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy Completed NCT00587067 Phase 2 FLOXURIDINE
18 Lenvatinib for Unresectable Intrahepatic Cholangiocarcinoma Recruiting NCT03801499 Phase 2 Lenvatinib
19 Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma Recruiting NCT03633773 Phase 1, Phase 2
20 A Trial of Systemic Chemotherapy in Combination With Conventional Transarterial Chemoembolization in Patients With Advanced Intra-Hepatic Cholangiocarcinoma Recruiting NCT02994251 Phase 2 gemcitabine;Cisplatin;Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C
21 Liver Transplantation for Early Intrahepatic Cholangiocarcinoma Recruiting NCT02878473 Phase 2
22 Derazantinib in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03230318 Phase 2 derazantinib
23 Lenvatinib Plus PD-1 Antibody for Unresectable ICC Recruiting NCT03779100 Phase 2 Lenvatinib;PD-1 antibody
24 Drug-Eluting Bead, Irinotecan Therapy for Unresectable Intrahepatic Cholangiocarcinoma w/Concomitant Gemcitabine and Cisplatin or Carboplatin Recruiting NCT01648023 Phase 2 Gem-Cis or Gem-Carbo
25 Hepatic Arterial Infusion (HAI) With Floxuridine (FUDR) and Dexamethasone (Dex) Combined With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma (ICC) Recruiting NCT01862315 Phase 2 Floxuridine (FUDR);dexamethasone;Gemcitabine;Oxaliplatin
26 A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma Recruiting NCT03521219 Phase 2 Apatinib
27 Gemcitabine, Cisplatin, and Nab-Paclitaxel Before Surgery in Patients With High-Risk Liver Bile Duct Cancer Recruiting NCT03579771 Phase 2 Cisplatin;Gemcitabine;Nab-paclitaxel
28 Treatment for Bile Duct Cancer in the Liver Recruiting NCT02167711 Phase 2 SIRT Yttrium-90
29 A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Recruiting NCT03684811 Phase 1, Phase 2 FT-2102;Azacitidine;Gemcitabine and Cisplatin
30 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
31 A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations Recruiting NCT03781934 Phase 1, Phase 2 MIV-818
32 SHR-1210 in Combination With GEMOX in Patients With Advanced BTC Recruiting NCT03486678 Phase 2 SHR-1210+GEMOX
33 Ramucirumab for Advanced Pre-Treated Biliary Cancers Recruiting NCT02520141 Phase 2 Ramucirumab
34 Nal-IRI With 5-fluorouracil (5-FU) and Leucovorin or Gemcitabine Plus Cisplatin in Advanced Biliary-tract Cancer Recruiting NCT03044587 Phase 2 Arm NaI-IRI + 5-FU + Leucovorin (Arm A);Arm Cisplatin + Gemcitabine (Arm B)
35 Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) Recruiting NCT02465060 Phase 2 Adavosertib;Afatinib;Binimetinib;Capivasertib;Crizotinib;Dabrafenib;Dasatinib;Defactinib;FGFR Inhibitor AZD4547;Larotrectinib;Osimertinib;Palbociclib;PI3K-beta Inhibitor GSK2636771;Sapanisertib;Sunitinib Malate;Taselisib;Trametinib;Vismodegib
36 Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations Active, not recruiting NCT01752920 Phase 1, Phase 2 ARQ 087
37 Gemcitabine, Cisplatin, and Abraxane in Advanced Biliary Cancers Active, not recruiting NCT02392637 Phase 2 Abraxane (Nab-Paclitaxel);Cisplatin;Gemcitabine
38 Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma Not yet recruiting NCT03364530 Phase 2 Gemcitabine-Oxaliplatin Regimen
39 Melphalan for Use With the Hepatic Delivery System Treatment in Patients With Unresectable Hepatocellular Carcinoma or Intra Hepatic Cholangiocarcinoma Suspended NCT02415036 Phase 2 Melphalan
40 Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer Suspended NCT03201458 Phase 2 Atezolizumab;Cobimetinib
41 Low-Dose Radiation Therapy to the Whole Liver With Gemcitabine and Cisplatin in IHC Terminated NCT02254681 Phase 2 Gemcitabine;Cisplatin
42 Second-line Therapy of Unresectable Cholangiocarcinoma by RADIOEMBOLIZATION Terminated NCT01383746 Phase 1, Phase 2
43 Response of Hepatic Tumors to Radioembolization Withdrawn NCT01775280 Phase 2
44 Stereotactic Body Radiotherapy for Hepatocellular Carcinoma, and Intrahepatic Cholangiocarcinoma Completed NCT01668134 Phase 1
45 ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed by Surgery Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
46 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma Recruiting NCT02834780 Phase 1 H3B-6527
47 Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma Recruiting NCT01525069 Phase 1 Floxuridine;Dexamethasone;Gemcitabine;Oxaliplatin
48 Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Recruiting NCT03257761 Phase 1 Guadecitabine
49 Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab, CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Recruiting NCT03267940 Phase 1 PEGPH20;CIS;GEM;Atezolizumab
50 Hepatic Arterial Infusion With Floxuridine and Dexamethasone in Combination With Gemcitabine as Adjuvant Treatment After Resection of Intrahepatic Cholangiocarcinoma Active, not recruiting NCT01938729 Phase 1 FLOXURIDINE;DEXAMETHASONE;GEMCITABINE

Search NIH Clinical Center for Intrahepatic Cholangiocarcinoma

Cochrane evidence based reviews: cholangiocarcinoma

Genetic Tests for Intrahepatic Cholangiocarcinoma

Anatomical Context for Intrahepatic Cholangiocarcinoma

MalaCards organs/tissues related to Intrahepatic Cholangiocarcinoma:

41
Liver, Lymph Node, Neutrophil, T Cells, Endothelial, Colon, Lung

Publications for Intrahepatic Cholangiocarcinoma

Articles related to Intrahepatic Cholangiocarcinoma:

(show top 50) (show all 1885)
# Title Authors Year
1
Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma. ( 30466151 )
2019
2
Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection. ( 30480811 )
2019
3
Preoperative drainage for perihilar cholangiocarcinoma. ( 30527574 )
2019
4
Preoperative drainage for perihilar cholangiocarcinoma. ( 30527575 )
2019
5
Preoperative drainage for perihilar cholangiocarcinoma - Authors' reply. ( 30527576 )
2019
6
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments. ( 30528800 )
2019
7
Mouse Model for Hepatocellular Carcinoma and Cholangiocarcinoma Originated from Mature Hepatocytes. ( 30536104 )
2019
8
Mouse Model for Cholangiocarcinoma from Peribiliary Glands. ( 30536105 )
2019
9
S100A11 promotes cell proliferation via P38/MAPK signaling pathway in intrahepatic cholangiocarcinoma. ( 30182496 )
2019
10
Enhancement Patterns of Intrahepatic Cholangiocarcinoma on Contrast-Enhanced Ultrasound: Correlation with Clinicopathologic Findings and Prognosis. ( 30292461 )
2019
11
Osteopontin promotes metastasis of intrahepatic cholangiocarcinoma through recruiting MAPK1 and mediating Ser675 phosphorylation of I^-Catenin. ( 29415992 )
2018
12
Induction of differentiation of intrahepatic cholangiocarcinoma cells to functional hepatocytes using an organoid culture system. ( 29434290 )
2018
13
MicroRNA-26b-5p regulates cell proliferation, invasion and metastasis in human intrahepatic cholangiocarcinoma by targeting S100A7. ( 29387225 )
2018
14
Characterization and prognostic significance of mortalin, Bcl-2 and Bax in intrahepatic cholangiocarcinoma. ( 29434920 )
2018
15
Challenges of surgical management of intrahepatic cholangiocarcinoma. ( 29911912 )
2018
16
Impact of viral hepatitis B status on outcomes of intrahepatic cholangiocarcinoma: a meta-analysis. ( 29947010 )
2018
17
Thermal ablation of intrahepatic cholangiocarcinoma: Safety, efficacy, and factors affecting local tumor progression. ( 29869103 )
2018
18
Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. ( 29874985 )
2018
19
Role of palliative radiotherapy in unresectable intrahepatic cholangiocarcinoma: population-based analysis with propensity score matching. ( 29942151 )
2018
20
Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. ( 29887261 )
2018
21
Tumor-associated macrophages recruited by periostin in intrahepatic cholangiocarcinoma stem cells. ( 29805605 )
2018
22
Small intestinal obstruction due to the metastasis of intrahepatic cholangiocarcinoma: A case report. ( 29561438 )
2018
23
Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. ( 29935812 )
2018
24
Prognostic comparison of the 7th and 8th editions of the American Joint Commission on Cancer staging system for intrahepatic cholangiocarcinoma. ( 29450978 )
2018
25
RA190, a Proteasome Subunit ADRM1 Inhibitor, Suppresses Intrahepatic Cholangiocarcinoma by Inducing NF-KB-Mediated Cell Apoptosis. ( 29913454 )
2018
26
Upregulation of long nona89coding RNA CCAT2 indicates a poor prognosis and promotes proliferation and metastasis in intrahepatic cholangiocarcinoma. ( 29393466 )
2018
27
The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma. ( 29862152 )
2018
28
Nab-paclitaxel is effective against intrahepatic cholangiocarcinoma via disruption of desmoplastic stroma. ( 29963132 )
2018
29
B7-H3 expression and its correlation with clinicopathologic features, angiogenesis, and prognosis in intrahepatic cholangiocarcinoma. ( 29696716 )
2018
30
Comparison of the sixth and the seventh editions of the UICC classification for intrahepatic cholangiocarcinoma. ( 29859128 )
2018
31
Assessment of the Lymph Node Status in Patients Undergoing Liver Resection for Intrahepatic Cholangiocarcinoma: the New Eighth Edition AJCC Staging System. ( 28424987 )
2018
32
Blocking of the EGFR-STAT3 signaling pathway through afatinib treatment inhibited the intrahepatic cholangiocarcinoma. ( 29805522 )
2018
33
Towards Personalized Medicine for Intrahepatic Cholangiocarcinoma: Pharmacogenomic Stratification of Patients. ( 29394502 )
2018
34
Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. ( 29299649 )
2018
35
Impact of serum CA19-9 level on prognosis and prediction of lymph node metastasis in patients with intrahepatic cholangiocarcinoma. ( 29427472 )
2018
36
Intrahepatic cholangiocarcinoma after Fontan procedure in an adult with visceral heterotaxy. ( 29559246 )
2018
37
Y90 radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. ( 29448165 )
2018
38
Elevated TRIM44 promotes intrahepatic cholangiocarcinoma progression by inducing cell EMT via MAPK signaling. ( 29446253 )
2018
39
Optimal extent of surgical and pathologic lymph node evaluation for resected intrahepatic cholangiocarcinoma. ( 29370972 )
2018
40
Overexpression of IL-35 in intrahepatic cholangiocarcinoma isa prognostic indicator after curative resection. ( 29446854 )
2018
41
Transcriptomic analysis and mutational status of IDH1 in paired primary-recurrent intrahepatic cholangiocarcinoma. ( 29871612 )
2018
42
Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma? ( 29395023 )
2018
43
Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. ( 29398035 )
2018
44
Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. ( 29408647 )
2018
45
Long-term outcomes of patients with intraductal growth sub-type of intrahepatic cholangiocarcinoma. ( 29958811 )
2018
46
Tourniquet-ALPPS is a promising treatment for very large hepatocellular carcinoma and intrahepatic cholangiocarcinoma. ( 29963276 )
2018
47
Correction to: Prognostic Factors in Overall Survival of Patients with Unresectable Intrahepatic Cholangiocarcinoma Treated by Means of Yttrium-90 Radioembolization: Results in Therapy-NaA^ve Patients. ( 29380003 )
2018
48
The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. ( 29903509 )
2018
49
Budd-Chiari Syndrome and Esophageal Achalasia: Unrecognized Intrahepatic Cholangiocarcinoma Invading Multiple Organs. ( 29526953 )
2018
50
Successful Secondary Engraftment of Pancreatic Ductal Adenocarcinoma and Cholangiocarcinoma Patient-Derived Xenografts After Previous Failed Primary Engraftment. ( 30273859 )
2018

Variations for Intrahepatic Cholangiocarcinoma

ClinVar genetic disease variations for Intrahepatic Cholangiocarcinoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 APC NM_000038.5(APC): c.8332G> T (p.Ala2778Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587778046 GRCh37 Chromosome 5, 112179623: 112179623
2 APC NM_000038.5(APC): c.8332G> T (p.Ala2778Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs587778046 GRCh38 Chromosome 5, 112843926: 112843926
3 APC NM_000038.5(APC): c.4440G> C (p.Gln1480His) single nucleotide variant Uncertain significance rs876659881 GRCh38 Chromosome 5, 112840034: 112840034
4 APC NM_000038.5(APC): c.4440G> C (p.Gln1480His) single nucleotide variant Uncertain significance rs876659881 GRCh37 Chromosome 5, 112175731: 112175731
5 APC NM_001127511.2(APC): c.8407G> A (p.Asp2803Asn) single nucleotide variant Uncertain significance GRCh37 Chromosome 5, 112179752: 112179752
6 APC NM_001127511.2(APC): c.8407G> A (p.Asp2803Asn) single nucleotide variant Uncertain significance GRCh38 Chromosome 5, 112844055: 112844055

Expression for Intrahepatic Cholangiocarcinoma

Search GEO for disease gene expression data for Intrahepatic Cholangiocarcinoma.

Pathways for Intrahepatic Cholangiocarcinoma

GO Terms for Intrahepatic Cholangiocarcinoma

Cellular components related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC4

Biological processes related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of cellular senescence GO:2000774 9.43 KRAS MIR22
2 O-glycan processing GO:0016266 9.43 MUC1 MUC2 MUC4
3 maintenance of gastrointestinal epithelium GO:0030277 9.4 MUC2 MUC4
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.37 MUC1 TP53
5 NADP metabolic process GO:0006739 9.32 IDH1 IDH2
6 isocitrate metabolic process GO:0006102 9.16 IDH1 IDH2
7 glyoxylate cycle GO:0006097 8.96 IDH1 IDH2
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 8.92 KRAS MUC1 MUC2 MUC4

Molecular functions related to Intrahepatic Cholangiocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 isocitrate dehydrogenase (NADP+) activity GO:0004450 8.96 IDH1 IDH2
2 isocitrate dehydrogenase activity GO:0004448 8.62 IDH1 IDH2

Sources for Intrahepatic Cholangiocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....